Harvard Bioscience, Inc. (HBIO) NASDAQ
5.55
+0.15(+2.78%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
5.55
+0.15(+2.78%)
Currency In USD
| Previous Close | 5.4 |
| Open | 5.45 |
| Day High | 5.58 |
| Day Low | 5.41 |
| 52-Week High | 9.5 |
| 52-Week Low | 2.8 |
| Volume | 17,247 |
| Average Volume | 48,957 |
| Market Cap | 24.82M |
| PE | -0.43 |
| EPS | -12.8 |
| Moving Average 50 Days | 5.39 |
| Moving Average 200 Days | 5.4 |
| Change | 0.15 |
Harvard Bioscience Announces Reverse Stock Split
GlobeNewswire Inc.
Mar 06, 2026 9:01 PM GMT
Harvard Bioscience’s common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), a
Harvard Bioscience to Participate in KeyBanc’s Virtual Healthcare Forum
GlobeNewswire Inc.
Mar 03, 2026 12:30 PM GMT
HOLLISTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Interim Chief Financial Officer, will be participating in KeyBanc Ca
Harvard Bioscience Schedules Fourth Quarter 2025 Earnings Conference Call for March 12, 2026 at 8:00 AM ET
GlobeNewswire Inc.
Feb 26, 2026 12:30 PM GMT
HOLLISTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2025, before the market opens on March 12, 2026, and will hold a conference call to d